Dyslipidemia

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹.

A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.

Watch the video tackling the critical topic of dyslipidemia management post-acute coronary syndrome. Globally, despite its pivotal role in secondary prevention, the approach remains suboptimal, so we'll dissect Arafah MR et al recent publication, providing a detailed evaluation of lipid management after ACS in Saudi Arabia. Specifically, shining a spotlight on LDL-cholesterol management and delve into the complications of statin use in post-ACS Saudi patients.

Prescription patterns of lipidlowering therapies over time in patients with atherosclerotic cardiovascular disease

Findings from Gould study

Highlights on the most recent real-world data on the use of PCSK9 inhibitors, including those from the Swedeheart and AIFA registries.